Lexicon will present results from a post hoc analysis of sotagliflozin in type 1 diabetes as a short oral presentation on March 12, 2026, at the 19th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD). The ATTD congress is scheduled for March 11-14, 2026, in Barcelona, Spain. Related materials include the event announcement on GlobeNewswire and the STENO1 trial listing at Clinicaltrials.gov.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexicon Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603110800PRIMZONEFULLFEED9669689) on March 11, 2026, and is solely responsible for the information contained therein.
Comments